Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Stage |
Gleason Grade |
Gleason Score |
TNM |
Type † |
|
A1 |
1 |
M |
60 |
Prostate |
Adenocarcinoma |
1 |
II |
1 |
1+2 |
T3aN0M0 |
Malignant |
|
A2 |
2 |
M |
71 |
Prostate |
Adenocarcinoma |
1 |
II |
1 |
1+1 |
T2N0M0 |
Malignant |
|
A3 |
3 |
M |
72 |
Prostate |
Adenocarcinoma |
2 |
II |
3 |
3+3 |
T2N0M0 |
Malignant |
|
A4 |
4 |
M |
74 |
Prostate |
Adenocarcinoma |
2 |
IV |
3 |
2+3 |
T4N1M1c |
Malignant |
|
A5 |
5 |
M |
60 |
Prostate |
Adenocarcinoma |
1 |
IV |
2 |
1+2 |
T4N1M1c |
Malignant |
|
A6 |
6 |
M |
70 |
Prostate |
Adenocarcinoma |
2 |
II |
3 |
2+3 |
T2aN0M0 |
Malignant |
|
A7 |
7 |
M |
70 |
Prostate |
Adenocarcinoma |
2 |
IV |
3 |
2+3 |
T2N1M1c |
Malignant |
|
A8 |
8 |
M |
61 |
Prostate |
Adenocarcinoma |
2 |
III |
3 |
3+3 |
T3N1M0 |
Malignant |
|
A9 |
9 |
M |
65 |
Prostate |
Adenocarcinoma |
2 |
II |
3 |
3+4 |
T2N0M0 |
Malignant |
|
A10 |
10 |
M |
76 |
Prostate |
Adenocarcinoma |
2 |
II |
3 |
2+4 |
T2aN0M0 |
Malignant |
|
B1 |
11 |
M |
62 |
Prostate |
Adenocarcinoma |
2–3 |
IV |
3–4 |
3+4 |
T3N1M1b |
Malignant |
|
B2 |
12 |
M |
26 |
Prostate |
Adenocarcinoma |
2 |
II |
3 |
2+3 |
T2N0M0 |
Malignant |
|
B3 |
13 |
M |
76 |
Prostate |
Adenocarcinoma |
2 |
III |
3 |
3+3 |
T3N1M0 |
Malignant |
|
B4 |
14 |
M |
81 |
Prostate |
Adenocarcinoma |
2 |
III |
3 |
3+3 |
T3aN0M0 |
Malignant |
|
B5 |
15 |
M |
80 |
Prostate |
Adenocarcinoma |
2–3 |
IV |
3–4 |
3+4 |
T2N1M1c |
Malignant |
|
B6 |
16 |
M |
64 |
Prostate |
Adenocarcinoma |
2 |
II |
3 |
2+3 |
T2N0M0 |
Malignant |
|
B7 |
17 |
M |
64 |
Prostate |
Adenocarcinoma |
2 |
IV |
3 |
3+3 |
T3N0M1 |
Malignant |
|
B8 |
18 |
M |
75 |
Prostate |
Adenocarcinoma |
2–3 |
IV |
3–4 |
3+4 |
T2N1M1c |
Malignant |
|
B9 |
19 |
M |
73 |
Prostate |
Adenocarcinoma (hyperplasia) |
– |
III |
– |
– |
T3N1M1 |
Malignant |
|
B10 |
20 |
M |
65 |
Prostate |
Adenocarcinoma |
3 |
IV |
3–4 |
3+4 |
T2N1M1 |
Malignant |
|
C1 |
21 |
M |
75 |
Prostate |
Adenocarcinoma |
1 |
IV |
1 |
1+2 |
T4N1M1 |
Malignant |
|
C2 |
22 |
M |
69 |
Prostate |
Adenocarcinoma |
1 |
III |
1 |
1+2 |
T3bN0M0 |
Malignant |
|
C3 |
23 |
M |
82 |
Prostate |
Adenocarcinoma |
3 |
II |
4 |
4+5 |
T2N0M0 |
Malignant |
|
C4 |
24 |
M |
72 |
Prostate |
Adenocarcinoma |
3 |
IV |
4 |
4+5 |
T2N0M1 |
Malignant |
|
C5 |
25 |
M |
67 |
Prostate |
Adenocarcinoma |
3 |
III |
4 |
4+4 |
T2N2M0 |
Malignant |
|
C6 |
26 |
M |
60 |
Prostate |
Adenocarcinoma |
4 |
II |
5 |
5+5 |
T2N0M0 |
Malignant |
|
C7 |
27 |
M |
40 |
Prostate |
Adenocarcinoma (sparse) |
1 |
IV |
2 |
1+2 |
T2N1M1 |
Malignant |
|
C8 |
28 |
M |
78 |
Prostate |
Adenocarcinoma |
4 |
IV |
5 |
5+4 |
T4N1M1 |
Malignant |
|
C9 |
29 |
M |
69 |
Prostate |
Adenocarcinoma |
4 |
IV |
5 |
5+5 |
T4N0M1 |
Malignant |
|
C10 |
30 |
M |
87 |
Prostate |
Adenocarcinoma |
4 |
II |
5 |
5+5 |
T2N0M0 |
Malignant |
|
D1 |
31 |
M |
69 |
Prostate |
Small acinous carcinoma |
2 |
II |
3 |
2+3 |
T2N0M0 |
Malignant |
|
D2 |
32 |
M |
70 |
Prostate |
Small acinous carcinoma |
3 |
II |
4 |
4+4 |
T2N0M0 |
Malignant |
|
D3 |
33 |
M |
63 |
Rib bone |
Metastatic adenocarcinoma |
2–3 |
– |
– |
– |
– |
Metastasis |
|
D4 |
34 |
M |
62 |
Lymph node |
Metastatic adenocarcinoma |
3 |
– |
– |
– |
– |
Metastasis |
|
D5 |
35 |
M |
78 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
D6 |
36 |
M |
67 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
D7 |
37 |
M |
66 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
D8 |
38 |
M |
72 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
D9 |
39 |
M |
78 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
D10 |
40 |
M |
56 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E1 |
41 |
M |
72 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E2 |
42 |
M |
65 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E3 |
43 |
M |
69 |
Prostate |
Hyperplasia (adenocarcinoma) |
1 |
– |
– |
– |
– |
Malignant |
|
E4 |
44 |
M |
73 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E5 |
45 |
M |
77 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E6 |
46 |
M |
56 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E7 |
47 |
M |
69 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E8 |
48 |
M |
60 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E9 |
49 |
M |
70 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
E10 |
50 |
M |
64 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F1 |
51 |
M |
72 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F2 |
52 |
M |
70 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F3 |
53 |
M |
62 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F4 |
54 |
M |
74 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F5 |
55 |
M |
67 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F6 |
56 |
M |
69 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F7 |
57 |
M |
71 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F8 |
58 |
M |
68 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F9 |
59 |
M |
72 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
F10 |
60 |
M |
71 |
Prostate |
Hyperplasia |
– |
– |
– |
– |
– |
Malignant |
|
G1 |
61 |
M |
73 |
Prostate |
Chronic inflammation |
– |
– |
– |
– |
– |
Malignant |
|
G2 |
62 |
M |
84 |
Prostate |
Chronic inflammation |
– |
– |
– |
– |
– |
Malignant |
|
G3 |
63 |
M |
64 |
Prostate |
Chronic inflammation |
– |
– |
– |
– |
– |
Malignant |
|
G4 |
64 |
M |
69 |
Prostate |
Chronic inflammation |
– |
– |
– |
– |
– |
Malignant |
|
G5 |
65 |
M |
68 |
Prostate |
Chronic inflammation |
– |
– |
– |
– |
– |
Malignant |
|
G6 |
66 |
M |
82 |
Prostate |
Chronic inflammation |
– |
– |
– |
– |
– |
Malignant |
|
G7 |
67 |
M |
25 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
– |
– |
NAT |
|
G8 |
68 |
M |
21 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
– |
– |
NAT |
|
G9 |
69 |
M |
27 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
– |
– |
NAT |
|
G10 |
70 |
M |
64 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
– |
– |
NAT |
|
H1 |
71 |
M |
77 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
– |
– |
NAT |
|
H2 |
72 |
M |
80 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
– |
– |
NAT |
|
H3 |
73 |
M |
40 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
H4 |
74 |
M |
37 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
H5 |
75 |
M |
33 |
Prostate |
Normal prostate tissue (sparse) |
– |
– |
– |
– |
– |
Normal |
|
H6 |
76 |
M |
35 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
H7 |
77 |
M |
28 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
H8 |
78 |
M |
40 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
H9 |
79 |
M |
35 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
H10 |
80 |
M |
45 |
Prostate |
Normal prostate tissue |
– |
– |
– |
– |
– |
Normal |
|
–
|
– |
M |
58 |
Skin |
Malignant melanoma (tissue marker) |
– |
|
|
|
|
Malignant |
† For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
TNM grading:
T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum
N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes
M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis
